Spain - 33600000-6 Pharmaceuticals CCA.6CQCW5D PNAMSP 4/2024 FRAMEWORK AGREEMENT WITH A SINGLE COMPANY SETTING THE TERMS AND CONDITIONS FOR THE SUCCESSIVE SUPPLY AND UNIT PRICE OF THE EXCLUSIVE MEDICATION: CD3+ AUTOLYC CELLS...
For more information and to make a bid you will need to go to the third party website.
Details
Provided by
- Opportunity closing date
- 05 August 2024
- Opportunity publication date
- 05 July 2024
- Value of contract
- £1m-5m
- Your guide to exporting
Description
CCA.6CQCW5D PNAMSP 4/2024 FRAMEWORK AGREEMENT WITH A SINGLE COMPANY SETTING THE TERMS AND CONDITIONS FOR THE SUCCESSIVE SUPPLY AND UNIT PRICE OF THE EXCLUSIVE MEDICATION: CD3+ CELLS TRANSDUCED SELF TRANSDUCED ANTI CD19 100MILL CELLS/INYECTABLE IV 68 ML- Capacity:68; Pharmaceutical form: IV INJECTABLE (TECARTUS 0.4 - 2 X 10E8 1 BAG OF 68ML DISPERSION CELLS FOR PERFUSION /E729969), FOR THE VIRGEN DEL ROCÍO UNIVERSITY HOSPITAL, CENTER ATTACHED TO THE SEVILLE PROVINCIAL PROCUREMENT CENTER (CPC-SE), BY NEGOTIATED PROCEDURE WITHOUT PUBLICITY. Tender amount (VAT excluded) : 2.424.041,63€.
- Opportunity closing date
- 05 August 2024
- Value of contract
- £1m-5m
About the buyer
- Address
- Servicio Andaluz de Salud
The deadline to apply for this opportunity has passed.
Visit the
opportunities page
to find another.